Radioresistance in Prostate Cancer: Focus on the Interplay between NF-κB and SOD

Prostate cancer occurs frequently in men and can often lead to death. Many cancers, including prostate cancer, can be initiated by oxidative insult caused by free radicals and reactive oxygen species. The superoxide dismutase family removes the oxygen-derived reactive oxygen species, and increased superoxide dismutase activity can often be protective against prostate cancer. Prostate cancer can be treated in a variety of ways, including surgery, androgen deprivation therapy, radiation therapy, and chemotherapy. The clinical trajectory of prostate cancer varies from patient to patient, but more aggressive tumors often tend to be radioresistant. This is often due to the free-radical and reactive-oxygen-species-neutralizing effects of the superoxide dismutase family. Superoxide dismutase 2, which is especially important in this regard, can be induced by the NF-kappa B pathway, which is an important mechanism in radioresistance. This information has enabled the development of interventions that manipulate the NF-kappa B mechanism to treat prostate cancer.

Automated summary

Prostate cancer is common in men, and oxidative stress caused by free radicals and reactive oxygen species could be a contributing factor. The superoxide dismutase family plays a crucial role in removing oxygen-derived reactive oxygen species, and increased superoxide dismutase activity may have a protective effect against prostate cancer. Understanding the role of superoxide dismutase in radioresistance has led to the development of interventions targeting the NF-kappa B pathway for prostate cancer treatment.